Diltiazem-like calcium entry blockers: A hypothesis of the receptor- binding site based on a comparative molecular field analysis model

Journal of Medicinal Chemistry

Volumn 40, Issue 1, 1997, Pages 125-131

  Corelli, Federico ^a   Manetti, Fabrizio ^a   Tafi, Andrea ^a   Campiani, Giuseppe ^a   Nacci, Vito ^a   Botta, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZEPINE DERIVATIVE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NITRENDIPINE; PYRROLO[2,1 D][1,4]BENZOTHIAZEPINE DERIVATIVE; PYRROLO[2,1 D][1,5]BENZOTHIAZEPINE DERIVATIVE; SESAMODIL FUMARATE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BINDING SITE; CARDIOVASCULAR DISEASE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CEREBRAL CORTEX; DILTIAZEM; MODELS, MOLECULAR; NITRENDIPINE; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZINES;

EID: 0031012989     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9605647     Document Type: Article

References (37)

1. Kendall, H. E.; Luscombe, D. K. Calcium Channel Blocking Drugs. In Progress in Medicinal Chemistry; Ellis, J. P., West, G. B., Eds.; Elsevier Science Publisher B.V.: Amsterdam, 1987; Vol. 24, pp 249-297.
2. (a) Janis, R. A.; Triggle, D. J. Drugs Acting on Calcium Channels. In Calcium Channels: Their Properties, Functions, Regulation, and Clinical Relevance; Hurtwitz, L., Partridge, L. D., Leach, J. K., Eds.; CRC Press: Boca Raton, FL, 1992; pp 197-249.
3. (b) Triggle, D. J. Calcium, Calcium Channels, and Calcium Channel Antagonists. Can. J. Physiol. Pharmacol. 1990, 68, 1474-1481.
4. Triggle, D. J.; Hawthorn, M.; Gopalakrishan, M.; Minarini, A.; Avery, S.; Rutledge, A.; Bangalore, R.; Zheng, W. Synthetic Organic Ligands Active at Voltage-Gated Calcium Channels. Ann. N. Y. Acad. Sci. 1991, 635, 123-138.
5. 2+ Complex. J. Med. Chem. 1993, 36, 1324-1332.
6. For a summary and leading references, see: Triggle, J. D. Drugs Acting on Ion Channels and Membranes. In Comprehensive Medicinal Chemistry; Hansch, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: New York, 1990; Vol. 3, pp 1047-1099.
7. Inoue, H.; Konda, M.; Hashiyama, T.; Otsuka, H.; Takahashi, K.; Gaino, M.; Date, T.; Aoe, K.; Takeda, M.; Murata, S.; Narita, H.; Nagao, T. Synthesis of Halogen-Substituted 1,5-Benzothiazepine Derivatives and Their Vasodilating and Hypotensive Activities. J. Med. Chem. 1991, 34, 675-687.
8. (a) Kurokawa, M.; Sato, F.; Fujiwara, I.; Hatano, N.; Honda, Y.; Yoshida, T.; Naruto, S.; Matsumoto, J.; Uno, H. A New Class of Calcium Antagonists. 2. Synthesis and Biological Activity of 11-[[4-(4-Fluoropnenyl)-1-piperazinyl]butyiyl]amino]-6,11-dihydrodibenzo[b,e] thiepin Maleate and Related Compounds. J. Med. Chem. 1991, 34, 927-934.
9. (b) Fujita, M.; Ho, S.; Ota, A.; Kato, N.; Yamamoto, K.; Kawashima, Y.; Yamauchi, H.; Iwao, J. Synthesis and Ca2+ Antagonistic Activity of 2-[2-[(Aminoalkyl)-oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H-1,4- benzothiazines. J. Med. Chem. 1990, 33. 1898-1905.
10. (c) Yamamoto, K.; Fujita, M.; Tabashi, K.; Kawashima, Y.; Kato, E.; Oya, M.; Iso, T.; Iwao, J. Novel Calcium Antagonists. Synthesis and Structure-Activity Relationship Studies of Benzothiazoline Derivatives. J. Med. Chem. 1988, 31, 919-930.
11. (d) Hashiyama, T.; Inoue, H.; Takeda, M.; Murata, S.; Nagao, T. Reactions of 3-Phenylglycidic Esters. V. Reaction of Methyl 3-(4-Methoxyphenyl)iglycidate with 2-Nitroaniline and Synthesis of 1,5-Benzodiazepine Derivatives. Chem. Pharm. Bull. 1985, 33, 2348-2358.
12. (a) Floyd, D. M.; Kimball, S. D.; Krapcho, J.; Das, J.; Turk, C. F.; Moquin, R. V.; Lago, M. W.; Duff, K. J.; Lee, V. G.; White, R. E.; Ridgewell, R. E.; Moreland, S.; Brittain, R. J.; Normandin, D. E.; Hedberg, S. A.; Cucinotta, G. G. Benzazepinone Calcium Channel Blockers. 2. Structure-Activity and Drug Metabolism Studies Leading to Potent Antihypertensive Agents. Comparison with Benzothiazepinones. J. Med. Chem. 1992, 35, 756-772.
13. (b) Das, J.; Floyd, D. M.; Kimball, S. D.; Duff, K. J.; Vu, T. C.; Moquin, R. V.; Gougoutas, J. Z.; Malley, M. F.; Moreland, S.; Brittain, R. J.; Hedberg, S. A.; Cucinotta, G. G. Benzazepinone Calcium Channel Blockers. 3. Synthesis and Structure-Activity Studies of 3-Alkyl Benzazepinones. J. Med. Chem. 1992, 35, 773-780.
14. (c) Kimball, S. D.; Floyd, D. M.; Das, J.; Hunt, J. T.; Krapcho, J.; Rovnyak, G.; Duff, K. J.; Lee, V. G.; Moquin, R. V.; Turk, C. F.; Hedberg, S. A.; Moreland, S.; Brittain, R. J.; McMullen, D. M.; Normandin, D. E.; Cucinotta, G. G. Benzazepinone Calcium Channel Blockers. 4. Structure-Activity Overview and Intracellular Binding Site. J. Med. Chem. 1992, 35, 781-793.
15. (d) Das, J.; Floyd, D. M.; Kimball, S. D.; Duff, K. J.; Lago, M. W.; Krapcho, J.; White, R. E.; Ridgewell, R. E.; Obermeier, M. T.; Moreland, S.; McMullen, D.; Normandin, D.; Hedberg, S. A.; Schaeffer, T. R. Benzazepinone Calcium Channel Blockers. 5. Effects on Antihypertensive Activity Associated with N1 and Aromatic Substituents. J. Med. Chem. 1992, 35, 2610-2617.
16. (e) Atwal, K. S.; Ahmed, S. Z.; Floyd, D. M.; Moreland, S.; Hedberg, A. (cis)-3-Methyl-1,5-benzothiazepine-4-ones: Potent Analogs of the Calcium Channel Blockers Diltiazem. Bioorg. Med. Chem. Lett. 1993, 3, 2797-2800.
17. Kimball, S. D.; Hunt, J. T.; Barrish, J. C.; Das, J.; Floyd, D. M.; Lago, M. W.; Lee, V. G.; Spergel, S. H.; Moreland, S.; Hedberg, S. A.; Gougoutas, J. Z.; Malley, M. F.; Lau, W. F. 1-Benzazepin-2-one Calcium Channel Blockers-VI. Receptor-Binding Model and Possible Relationship to Desmethoxyverapamil. Bioorg. Med. Chem. 1993, 1, 285-307.
18. Campiani, G.; Nacci, V.; Garofalo, A.; Botta, M.; Fiorini, I.; Tafi, A. Synthesis and Preliminary Biological Evaluation of 1-Aminomethyl-4-substituted-4H-pyrrolo[2,1-c][1,4]benzothiazines, A New Class of Calcium Antagonists. Bioorg. Med. Chem. Lett. 1992, 2, 1193-1198.
19. Campiani, G.; Garofalo, A.; Fiorini, I.; Nacci, V.; Botta, M.; Tafi, A. Synthesis and "In Vitro" Cardiovascular Activity of 4-Aryl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzothiazin-1-ones and 7-Acetoxy-6-phenyl-7a,8,9,10-tetrahydropyrrolo[2,1-d][1,5]-benzothiazepin-10- one. Bioorg. Med. Chem. Lett. 1994, 4, 1235-1240.
20. Campiani, G.; Garofaio, A.; Fiorini, I.; Botta, M.; Nacci, V.; Tafi, A.; Chianni, A.; Budriesi, R.; Bruni, G.; Romeo, M. R. Pyrrolo-[2,1-c][1,4]benzothiazines: Synthesis, Structure-Activity Relationships. Molecular Modeling Studies, and Cardiovascular Activity. J. Med. Chem. 1995, 38, 4393-4310.
21. 2+ Channel Blockers: A Study Using Conformational Analysis and Chemometric Methods. J. Comput.-Aided Mol. Des. 1991, 5, 571-584.
22. (a) van Wijngaarden, I.; Kruse. C. G.; van Hes, R.; van der Heyden, J. A. M.; Tulp, M. M. 2-Phenylpyrroles as Conformationally Restricted Benzamide Analogues. A New Class of Potential Antipsychotics. 1. J. Med. Chem. 1987, 30, 2099-2104.
23. (b) van Wijngaarden, I.; Kruse, C. G.; van der Heyden, J. A. M.; Tulp, M. M. 2-Phenylpyrroles as Conformationally Restricted Benzamide Analogues. A New Class of Potential Antipsychotics. 2. J. Med. Chem. 1988, 31, 1934-1940.
24. (c) For a definition of isosteric and nonisosteric bioanalogy, see: Burger, A. Isosterism and Bioanalogy in Drug Design. Med. Chem. Res. 1994, 4, 89-92.
25. (a) Tafi, A.; Anastassopoulos, J.; Theophanides, T.; Botta, M.; Corelli, F.; Massa, S.; Artico, M.; Costi, R.; Di Santo, R.; Ragno, R. Molecular Modeling of Azole Antifungal Agents Active Against Candida albicans. 1. A Comparative Molecular Field Analysis Study. J. Med. Chem. 1996, 39, 1227-1235.
26. (b) Greco, G.; Novellino, E.; Fiorini, I.; Nacci, V.; Campiani, G.; Ciani, S. M.; Garofalo, A.; Bernasconi, P.; Mennini, T. A Comparative Molecular Field Analysis Model for 6-Arylpyrrolo[2,1-d][1,5]-benzothiazepines Binding Selectively to the Mitochondrial Benzodiazepine Receptor. J. Med. Chem. 1994, 37, 4100-4108.
27. (c) DePriest, S. A.; Mayer, D.; Naylor, C. B.; Marshall, G. R. 3D-QSAR of Angiotensin-Converting and Thermolysin Inhibitors: a Comparison of CoMFA Models Based on Deduced and Experimentallv Determined Active Site Geometries. J. Am. Chem. Soc. 1993, 115, 5372-5384.
28. Kojic-Prodic, B.; Ruzic-Toros, Z.; Sunjic, V.; Decorte, E.; Moimas, F. Absolute Conformation and Configuration of (2S,3S)-3-Acetoxy-5-(dimethylaminoethyl)-2-14-methoxyphenyl)-2,3-dihydro-1,5- benzothiazepin-4(5H)-one Chloride (Diltiazem Hydrochloride). Helv. Chim. Acta 1984, 67, 916-926.
29. Steliou, K. MODEL (version 2.991) and BKMDL, Boston University, MA.
30. MODEL has been largely used especially when aromatic rings are in the molecules. For examples, see: (a) Botta, B.; Di Giovanni, M. C.; Delle Monache, G.; De Rosa, M. C.; Gacs-Baitz, E.; Botta, M.; Corelli, F.; Tafi, A.; Santini, A.; Benedetti, E.; Pedone, C.; Misiti, D. A Novel Route to Calix[4]arenes. 2. Solution- and Solid-State Structural Analyses and Molecular Modeling Studies. J. Org. Chem. 1994, 59, 1532-1541. (b) Massa, S.; Artico, M.; Mai, A.; Corelli, F.; Botta, M.; Tafi, A.; Pantaleoni, G. C.; Giorgi, R.; Coppolino, F.; Cagnotto, A.; Skorupska, M. Pyrrolobenzodiazepines and Related Systems. 2. Synthesis and Biological Properties of Isonoraptazepine Derivatives. J. Med. Chem. 1992, 35, 4533-4541.
31. MODEL has been largely used especially when aromatic rings are in the molecules. For examples, see: (a) Botta, B.; Di Giovanni, M. C.; Delle Monache, G.; De Rosa, M. C.; Gacs-Baitz, E.; Botta, M.; Corelli, F.; Tafi, A.; Santini, A.; Benedetti, E.; Pedone, C.; Misiti, D. A Novel Route to Calix[4]arenes. 2. Solution- and Solid-State Structural Analyses and Molecular Modeling Studies. J. Org. Chem. 1994, 59, 1532-1541. (b) Massa, S.; Artico, M.; Mai, A.; Corelli, F.; Botta, M.; Tafi, A.; Pantaleoni, G. C.; Giorgi, R.; Coppolino, F.; Cagnotto, A.; Skorupska, M. Pyrrolobenzodiazepines and Related Systems. 2. Synthesis and Biological Properties of Isonoraptazepine Derivatives. J. Med. Chem. 1992, 35, 4533-4541.
32. Sybyl (version 6.0) Molecular Modeling System, available from Tripos Associates Inc., 1699 S. Hanley Rd., St. Louis, MO 63144.
33. Stahle, L.; Wold, S. Partial Least Squares Analysis with Cross-Validation for the Two-Class Problem: a Monte Carlo Study. J. Chemom. 1987, 1, 185-196.
34. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E.; Frank, I. E. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
35. Campiani, G.; Fiorini, I.; De Filippis, M. P.; Ciani, S. M.; Garofalo, A.; Nacci, V.; Giorgi, G.; Sega, A.; Botta, M.; Chiarini, A.; Budriesi, R.; Bruni, G.; Romeo, R. M.; Manzoni, C.; Mennini, T. Cardiovascular Characterization of Pyrrolo[2,1-d][1,5]benzothiazepine Derivatives Binding Selectively to the Peripheral-Type Benzodiazepine Receptor (PBR): From Dual PBR Affinity and Calcium Antagonist Activity to Novel and Selective Calcium Entry Blockers. J. Med. Chem. 1996, 39, 2922-2938.
36. 2+ Antagonist Having a Benzothiazine Skeleton, and Structure-Activity Relationships. Bioorg. Med. Chem. 1994, 2, 235-242.
37. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape in Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.